GlassScriptPhysician profile
Timothy J Makatche
NPI 1265497259
$3,220.89
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $638 · 2021: $781.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $593.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $436.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $368.52 | 2019-2021 | |
| Pfizer INC. | $318.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.44 | 2019-2021 | |
| Abbvie INC. | $204.13 | 2019-2021 | |
| Amgen INC. | $203.08 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $114.00 | 2019-2021 | |
| Lilly USA, LLC | $110.17 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $98.11 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $90.42 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $84.66 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $77.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $65.66 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $51.76 | 2020-2021 | |
| Shire North American Group INC | $35.01 | 2019 | |
| Astellas Pharma US INC | $17.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Makatche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.